Background:Acinetobacter baumannii has become a significant problem in hospitals worldwide during the last decades. Biofilm formation is a virulence factor that may affect antibiotic resistance. This study aimed to elucidate the correlation between biofilm formation and biofilm‐related and oxacillinase genes in A . baumannii clinical isolates. Methods: This study was conducted on 53 A . baumannii isolates collected from hospitals affiliated with Babol University of Medical Sciences (Babol, Iran) from April to October 2023. Kirby–Bauer disc diffusion was used to determine antibacterial resistance. Biofilm formation was examined using crystal violet staining. Polymerase chain reaction was used to detect oxacillinase ( blaOXA−23 , blaOXA−24 , blaOXA−51 , and blaOXA−58 ) and biofilm‐encoding ( bap and blaPER−1 ) genes using specific primers. Results: The strains showed the highest resistance to trimethoprim/sulfamethoxazole and ciprofloxacin (98.11%) and the lowest resistance to ampicillin/sulbactam (66.03%). All isolates formed biofilms. Also, 67.92%, 18.86%, and 11.32% were strong, moderate, and weak biofilm producers, respectively. The frequencies of blaOXA−23 , blaOXA−24 , blaOXA−51 , bap , and blaPER−1 genes were 92.45%, 71.69%, 100%, 73.58%, and 58.49%, respectively. None of the isolates harbored blaOXA−58 . Conclusions: A high prevalence of antibiotic‐resistant strains was found among A . baumannii clinical isolates. There was no significant correlation between the clinical sample type and biofilm formation, but a notable link was found between antimicrobial resistance and biofilm formation, except for ciprofloxacin. Oxacillinase genes were not significantly correlated with biofilm formation, but biofilm production was associated with bap rather than blaPER−1 . Understanding the A . baumannii biofilm formation process is crucial for effective control of associated infections by targeting this mechanism.
The common side effects of COVID‐19 vaccination were mostly self‐restricted local reactions that quickly resolved. Nevertheless, rare autoimmune hepatitis cases have been reported in some vaccinated with mRNA COVID‐19 vaccines. This article presents a young man who developed fulminant hepatitis a few days after vaccination with the first dose of the AstraZeneca COVID‐19 vaccine. A 35‐year‐old man was admitted to our hospital with generalized weakness, abdominal pain, and jaundice. He received the first dose of the AstraZeneca COVID‐19 vaccine 8 days earlier. He was admitted to the hospital with a chief complaint of abdominal pain. On admission and because of his high D‐dimers, low platelet count, and low Fibrinogen level, vaccine‐induced immune thrombosis thrombocytopenia was suspected, which was ruled out later. Then, after a surge in his liver function tests, decreasing platelet, and abnormal clotting tests, fulminant hepatitis was considered for this patient. Several bacterial, viral, and autoimmune etiologies were then suspected, with all ruled out. Thus, fulminant hepatitis secondary to his AstraZeneca COVID‐19 vaccine was confirmed. Unfortunately, he died 3 days later of disseminated intravascular coagulopathy, after which a liver necropsy was performed, indicating drug/toxin‐induced hepatitis.
13 October 2021 in Iranian Journal of Microbiology
Acinetobacter baumannii is an opportunistic bacterial pathogen predominantly associated with hospital-acquired infections. Here we present a case of infective endocarditis of native Mitral and Aorta valves caused by A. baumannii in a 73-year-old man. He underwent surgical excision and Pathologic specimen showed A. baumannii growth after 48 hours that was exten- sively drug-resistant (XDR). He was treated with colistin and tigecycline. Finally, he discharged with no important compli- cation. To our best knowledge, it is the first case of Acinetobacter endocarditis has ever been reported in Iran. Although XDR A. baumannii is a life-threatening pathogen, proper and timely treatment can be life-saving.
Background: The World Health Organization (WHO) announced the SARS-COV-2 disease pandemic on March 9, 2020. With the advent of this disease, another health burden was added to about 37.9 million people in the world who are infected with HIV and are suffering from various diseases. These people may be at serious risk of COVID-19. Information about the effects of COVID-19 on people living with HIV, is limited. Case Presentation: We reported a 61-year-old man who was a known case of HIV from 6 years ago that was being treated with HAART (highly active antiretroviral therapy). He also had a history of Hodgkin’s lymphoma from 4 years ago who underwent autologous bone marrow transplantation (BMT) 2 weeks before given referral to our hospital. He complained of weakness, anorexia, and fever. RT-PCR for SARS-COV-2-RNA was positive in his nasopharyngeal and oropharyngeal swab. He was diagnosed with COVID-19 infection and treated with atazanavir. After one week, the patient discharged in a good general state. Conclusion: To the best of our knowledge, it is the first report of COVID-19 infection in an HIV positive patient after BMT in Iran. Despite his immunodeficiency, COVID-19 disease had mild manifestations and he had a good prognosis. We hope that our report and that of others can remain promising to doctors and HIV patients cross fingers for COVID-19 recovery.
26 June 2023 in Russian Journal of Infection and Immunity
Background. Although most people recover from acute COVID-19 within a few weeks, some have long-lasting clinical problems. The prevalence of these prolonged complications in kidney transplant (KT) recipients has not been determined. Materials and methods. Six months following of 148 patients with post-COVID-19 syndrome admitted to three centers in Iran (Tehran, Shiraz and Babol) that underwent KT were included in this study. Also, one-hundred COVID-19 patients without KT were included as the control group. The demographic data, medications, and disease course were recorded. The baseline and demographic characteristics were analyzed using the Chi-square test. Moreover, students t-test were utilized to compare case and control groups. Results. The total number of patients was 248, of which 148 were in the case groups. Hospitalization associated with COVID-19 was for all patients; besides, there were 18 patients in control and 24 case groups admitted to an intensive care unit (ICU). The most commonly reported symptom was fever. Multivariate analysis identified the history of chronic kidney disease, hypertension, cerebral vascular accident, and diabetes mellites as predictors for developing post-COVID clinical complications. Conclusion. Evidence shows the high commonness of post-COVID-19 syndrome among kidney transplant patients after COVID-19, and the most common symptoms were fever, chills, and myalgia. So, all patients recovered from acute COVID-19 should undergo long-term monitoring to evaluate and treat possible complications.